Larger tumor size and more advanced tumor stage are associated with an increased risk of intravesical recurrence among patients undergoing radical nephroureterectomy for in upper tract urothelial carcinoma.
Adjuvant platinum-based chemotherapy for upper tract urothelial carcinoma within 90-days of nephroureterectomy improves disease-free and metastasis-free survival compared with surveillance, a study found.
A combination of pembrolizumab and an antibody-drug conjugate demonstrated a 73% overall response rate in a phase 1/2 clinical trial.
The VES-13, a brief frailty screening tool, was found effective in determining which older patients with GU cancer were at higher risk for adverse outcomes and would benefit from a CGA.
Patients with GU malignancies were more likely to receive palliative care if they were in the West compared with other US regions.